Dysport Therapeutic in Canada: Uses Beyond Aesthetics

The Distinction of Dysport 

Dysport (the brand name for abobotulinumtoxinA) is one of the three primary formulations of Botulinum Toxin Type A (BoNT-A) approved for use in Canada. While all BoNT-A products share the same core mechanism, temporarily blocking nerve signals to the muscles or glands, they are distinct pharmaceuticals. This difference is critical for regulatory approvals, dosing, and patient outcomes.

Did you know?: Dysport is formulated differently, meaning its units are not equivalent to those of BOTOX or Xeomin. Proper dosing must always be based on Dysport units as prescribed by a trained professional.

Learn more about our Botox treatments in Langley

Health Canada Approved Therapeutic Indications for Dysport

In Canada, Dysport Therapeutic is primarily recognized and approved for the treatment of movement disorders. Its approved indications are:

1. Focal Spasticity

Spasticity is a condition where muscles become tight or stiff, often following a stroke, cerebral palsy, or spinal cord injury. Dysport helps by relaxing these overactive muscles, improving movement and reducing pain.

• Adults: Treatment of upper and lower limb spasticity associated with stroke.

• Pediatric Patients: Treatment of dynamic equinus foot deformity (a type of lower limb spasticity) in children aged two years and older with cerebral palsy.

2. Cervical Dystonia (Spasmodic Torticollis)

Cervical dystonia is a painful condition where neck muscles contract involuntarily, causing the head to twist or turn to one side. Dysport injections into the affected muscles help to reduce the severity of the abnormal head position and the associated neck pain.

Dysport and Off-Label Uses in Canada

An "off-label" use refers to a drug being prescribed for a condition that has not been formally approved by Health Canada. For many conditions, Dysport is used off-label based on clinical evidence and practitioner expertise.

1. Temporomandibular Joint (TMJ) Disorder & Bruxism

Dysport is widely used by trained dentists and specialists in Canada to treat TMJ-related pain and bruxism (teeth grinding/clenching).

• Use: It is injected into the masseter (jaw) and temporalis (temple) muscles to decrease excessive muscle contraction and reduce the pain, tension, and headaches associated with jaw clenching.

• Coverage Status: This application is generally considered off-label. As such, the procedure is often not covered by provincial health plans and is rarely covered by private insurance, making it primarily a self-pay treatment.

2. Chronic Migraine and Hyperhidrosis

It is crucial to note that Dysport is not the Health Canada-approved brand for the prophylaxis of Chronic Migraine or for Primary Axillary Hyperhidrosis (excessive underarm sweating).

• Chronic Migraine: BOTOX is the specific BoNT-A drug approved for this condition in Canada and is the one covered by drug plans following the PREEMPT Protocol.

• Hyperhidrosis: Similarly, BOTOX is the specific BoNT-A drug approved for severe primary axillary hyperhidrosis.

While a physician may legally use Dysport off-label for these conditions, it is important for a Canadian company to know that coverage and reimbursement for these specific conditions will almost certainly be denied by provincial or private drug plans if the claim is submitted using the non-approved product.

Canadian Coverage and Reimbursement Landscape

Access and coverage for Dysport in Canada are strictly tied to whether the use is one of its Health Canada-approved indications.

Provincial Drug Plans

Provincial formularies (e.g., Ontario Drug Benefit, BC PharmaCare) will cover the cost of Dysport Therapeutic for its approved indications, such as spasticity and cervical dystonia. Coverage is typically provided under Limited Use or Exceptional Access criteria, requiring the prescribing physician to meet certain specialist qualifications and submit detailed documentation.

Private Insurance

Private (extended health) insurance coverage for Dysport will generally align with the provincial formulary.

• Approved Use: High likelihood of coverage for the drug cost when treating an approved condition (e.g., spasticity).

• Off-Label Use: Low likelihood of coverage for off-label applications like TMJ/Bruxism, and near-certain denial for conditions where another BoNT-A product (BOTOX) holds the exclusive Canadian approval (e.g., chronic migraine).

Safety, Administration, and Product Differences

Due to its potent nature, Dysport must be administered by a healthcare professional with expertise and experience in the relevant condition and the anatomy of the injection site. Treatment should always be part of a comprehensive management plan. The safety profile is well-established, with most side effects being temporary and localized to the injection area.

For effective management and successful reimbursement in the Canadian context, using the specific Botulinum Toxin Type A product that aligns with Health Canada's approved indications is the best practice.